Last week, Cara Therapeutics reported that its phase 2b trial of CR845, an investigational new pain relief drug, had failed to meet its primary endpoint. Since then, the stock dropped from $26 to $15 a loss of over 40% of its value. Has the market over-reacted?
Cara Therapeutics' New Pain Drug Still Has Value After Failed Clinical Trial
Forbes - 6 Jul 2017 22:36
Last week, Cara Therapeutics reported that its phase 2b trial of CR845, an investigational new pain relief drug, had failed to meet its primary endpoint. Since then, the stock dropped from $26 to $15 a loss of over 40% of its value. Has the market over-reacted?
Share this Article
Recommended